The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).
A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use despite the availability of multiple treatment options.
Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, "Alexion") filed a complaint on January 3, 2024, against Samsung Bioepis Co. Ltd.
In the last month, there has been a flurry of activity at the PTAB related to challenges from biosimilar manufacturers related to ustekinumab, aflibercept, and eculizumab patents.
ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.